Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1533 ARTÍCULOS , VIENDO DEL 271 AL 285

Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer's disease

Agrawal M, Ajazuddin, Tripathi DK, Saraf S, Saraf S, Antimisiaris SG, Mourtas S, Hammarlund-Udenaes M, Alexander A.

J Control Release. 2017 Aug 28;260:61-77. doi: 10.1016/j.jconrel.2017.05.019. Epub 2017 May 24.

Targeting Free Radicals in Oxidative Stress-Related Human Diseases

Poprac P, Jomova K, Simunkova M, Kollar V, Rhodes CJ, Valko M.

Trends Pharmacol Sci. 2017 Jul;38(7):592-607. doi: 10.1016/j.tips.2017.04.005. Epub 2017 May 24.

Biosensors for Screening Kinase Inhibitors

Bhalla N, Estrela P.

Curr Top Med Chem. 2017;17(22):2470-2481. doi: 10.2174/1568026617666170531113233.

Can Co-Activation of Nrf2 and Neurotrophic Signaling Pathway Slow Alzheimer's Disease?

Murphy KE, Park JJ.

Int J Mol Sci. 2017 May 31;18(6):1168. doi: 10.3390/ijms18061168.

C9orf72 mutations do not influence the tau signature of amyotrophic lateral sclerosis with cognitive impairment (ALSci)

Volkening K, Strong WL, Seaton S, Yang W, Strong MJ.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Nov;18(7-8):549-554. doi: 10.1080/21678421.2017.1332075. Epub 2017 May 31.

The role of perivascular innervation and neurally mediated vasoreactivity in the pathophysiology of Alzheimer's disease

Nizari S, Romero IA, Hawkes CA.

Clin Sci (Lond). 2017 Jun 1;131(12):1207-1214. doi: 10.1042/CS20160769.

The novel multitarget iron chelating and propargylamine drug M30 affects APP regulation and processing activities in Alzheimer's disease models

Amit T, Bar-Am O, Mechlovich D, Kupershmidt L, Youdim MBH, Weinreb O.

Neuropharmacology. 2017 Sep 1;123:359-367. doi: 10.1016/j.neuropharm.2017.05.026. Epub 2017 May 29.

[Cataract surgery among 50 Alzheimer's patient (55 eyes)]

Girard B, Chouard B, Hardy F.

J Fr Ophtalmol. 2017 Jun;40(6):487-498. doi: 10.1016/j.jfo.2017.01.006. Epub 2017 May 29.

Cognitive training in Alzheimer's disease: a controlled randomized study

Giovagnoli AR, Manfredi V, Parente A, Schifano L, Oliveri S, Avanzini G.

Neurol Sci. 2017 Aug;38(8):1485-1493. doi: 10.1007/s10072-017-3003-9. Epub 2017 Jun 2.

Estrogen and Alzheimer's disease: Still an attractive topic despite disappointment from early clinical results

Merlo S, Spampinato SF, Sortino MA.

Eur J Pharmacol. 2017 Dec 15;817:51-58. doi: 10.1016/j.ejphar.2017.05.059. Epub 2017 May 31.

The underexplored question of β-amyloid monomers

Copani A.

Eur J Pharmacol. 2017 Dec 15;817:71-75. doi: 10.1016/j.ejphar.2017.05.057. Epub 2017 May 31.

Lorazepam Challenge for Individuals at Varying Genetic Risk for Alzheimer Disease

Stonnington CM, Harel B, Locke DEC, Hentz JG, Zhang N, Maruff P, Caselli RJ.

Alzheimer Dis Assoc Disord. 2017 Oct-Dec;31(4):271-277. doi: 10.1097/WAD.0000000000000200.

Small things matter: Implications of APP intracellular domain AICD nuclear signaling in the progression and pathogenesis of Alzheimer's disease

Bukhari H, Glotzbach A, Kolbe K, Leonhardt G, Loosse C, Müller T.

Prog Neurobiol. 2017 Sep;156:189-213. doi: 10.1016/j.pneurobio.2017.05.005. Epub 2017 Jun 3.

Neuropsychological Profiles Differentiate Alzheimer Disease from Subcortical Ischemic Vascular Dementia in an Autopsy-Defined Cohort

Ramirez-Gomez L, Zheng L, Reed B, Kramer J, Mungas D, Zarow C, Vinters H, Ringman JM, Chui H.

Dement Geriatr Cogn Disord. 2017;44(1-2):1-11. doi: 10.1159/000477344. Epub 2017 Jun 9.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias